IXHL Incannex Healthcare Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1873875 · Fiscal year ends 06/30
Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY69.0%
TTM EPS YoY97.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-20.7%
ROA-19.9%
ROIC (approx.)-1,944.8%
Asset turnover—
Leverage & solvency
Liabilities / assets6.0%
Debt / equity0.00x
Current ratio67.79x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.21x
Accruals ratio-15.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-06-30 | FY20252025-06-30 | FY20242024-06-30 | FY20232023-06-30 | FY2022*2022-06-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $0 | $86,000 | $12,000 | — | — |
| Cost of revenue | — | — | — | — | $6,338 |
| R&D expense | $5.21M | $10.75M | $12.88M | $6.31M | $5.37M |
| SG&A expense | $17.82M | $13.13M | $17.17M | $8.01M | — |
| Operating income | -$23.03M | -$23.79M | -$30.04M | -$49.67M | — |
| Interest expense | $0 | $303,000 | — | — | — |
| Pretax income | -$19.30M | -$46.88M | -$18.43M | -$48.81M | -$14.90M |
| Income tax | $0 | $0 | $30,000 | — | — |
| Net income | -$19.30M | -$46.88M | -$18.46M | -$48.81M | -$14.90M |
| EBITDA | -$22.79M | -$23.54M | -$29.94M | -$49.58M | — |
| EPS (basic) | -1.66 | -40.82 | -1.15 | -3.32 | -1.25 |
| EPS (diluted) | -1.66 | -40.82 | -1.15 | -3.32 | -1.25 |
| Weighted avg. shares (diluted) | 11.66M | 1.15M | 16.16M | 15.38M | — |
| Banking | |||||
| Deposits | — | — | — | — | $86.59M |
| Balance sheet | |||||
| Cash & equivalents | $67.71M | $15.04M | $5.86M | $22.12M | $25.83M |
| Receivables | — | — | — | $287,478 | $294,717 |
| Current assets | $72.83M | $19.96M | $16.20M | $23.00M | $37.88M |
| PP&E, net | $4,000 | $227,000 | $472,000 | $294,000 | — |
| Intangibles | — | — | — | $52.72M | — |
| Total assets | $72.98M | $20.45M | $17.05M | $23.78M | $37.88M |
| Current liabilities | $1.49M | $6.98M | $5.62M | $2.55M | $2.01M |
| Total liabilities | $5.61M | $7.06M | $5.83M | $2.96M | $2.01M |
| Shareholders' equity | $67.37M | $13.39M | $11.22M | $20.82M | $24.71M |
| Shares outstanding | 12.54M | 6.48M | 17.64M | 15.87M | — |
| Cash flow statement | |||||
| Operating cash flow | -$12.87M | -$12.51M | -$15.85M | -$10.75M | -$12.81M |
| Capital expenditure | $10,000 | $8,000 | $277,000 | $316,000 | — |
| Free cash flow | -$12.88M | -$12.52M | -$16.12M | -$11.06M | — |
| Investing cash flow | -$94,000 | -$8,000 | -$277,000 | -$316,000 | — |
| Financing cash flow | $65.90M | $21.40M | — | $8.18M | $41.18M |
| Depreciation & amortization | $240,000 | $246,000 | $103,000 | $88,000 | — |
| Stock-based compensation | $7.56M | $2.61M | $8.93M | $2.15M | $1.46M |
| Share buybacks | $9.40M | $0 | — | — | — |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.